Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Eli Lilly and Ypsomed have entered a global agreement to develop an automated insulin delivery system. Lilly will commercialize a version of Ypsomed's mylife™ YpsoPump®, already marketed in Europe since 2016. This system will also incorporate continuous glucose monitoring and utilize pre-filled cartridges for Lilly's rapid-acting insulins. Ypsomed aims for FDA clearance in 2022. With diabetes affecting over 34 million Americans, this partnership seeks to enhance diabetes management options.
- Global partnership with Ypsomed to develop an innovative automated insulin delivery system.
- Lilly will commercialize an established insulin pump in the U.S. and Europe.
- Integration of continuous glucose monitoring technology to enhance diabetes management.
- FDA clearance and commercial success of the insulin delivery system are not guaranteed.
BURGDORF, Switzerland and INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.
Ypsomed's insulin pump has been marketed in Europe since 2016. Available in 21 countries as the mylife™ YpsoPump®, this pump stands out for its small size and its unique, icon-based touch screen. Lilly will commercialize a version of this insulin pump, along with continuous glucose monitoring (CGM) and automated insulin delivery technology, in the United States and Europe. This pump will use pre-filled insulin cartridges for Lilly's rapid-acting insulins.
"Lilly is committed to delivering solutions that meet the needs of the diabetes community and providing more options to help them manage their diabetes," said Marie Schiller, vice president of product development for Connected Care and Insulins at Lilly. "People who use insulin, along with their healthcare providers, need simple, effective tools that lead to improved outcomes, and Ypsomed is developing an automated insulin delivery system with several exciting features that can help meet that need."
Ypsomed plans to submit a version of the mylife YpsoPump for clearance to the U.S. Food and Drug Administration for use in automated insulin delivery in 2022. If cleared, Lilly will have exclusive rights to commercialize the pump in the U.S.
"We are thrilled to partner with Lilly to bring our insulin pump to the United States and deliver improved outcomes to people with diabetes through connected solutions," said Simon Michel, CEO of Ypsomed. "Managing diabetes with insulin is already complex enough, so we developed this insulin pump to be easy to learn and easy to operate. Our goal is to support people living with diabetes through app-centric insulin management, CGM data and advanced algorithms. Partnering with Lilly to bring a holistic platform to market is an important next step in this journey that started in 1984 by introducing the world's first micro insulin pump to the market."
About Diabetes
Approximately 34 million Americans1 (just over 1 in 10) and an estimated 463 million adults worldwide2 have diabetes. Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone1. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes and related conditions. We work to deliver breakthrough outcomes through innovative solutions—from medicines and technologies to support programs and more. For the latest updates, visit http://www.lillydiabetes.com/ or follow us on Twitter: @LillyDiabetes and Facebook: LillyDiabetesUS.
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY
About the Ypsomed Group
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylifeTM Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates as a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs nearly 1,700 employees. Additional information is available under www.ypsomed.com.
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly and Ypsomed's agreement for Lilly to commercialize an insulin pump, developed and manufactured by Ypsomed, as part of Lilly's connected diabetes solutions, currently in development, and reflects Lilly's current beliefs. However, as with any pharmaceutical product or medical device, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there is no guarantee that Lilly's connected diabetes solutions will receive regulatory clearance or be commercially successful or that the company will meet its anticipated timelines for the roll out of this platform. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
1 Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services; 2020.
2 International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation, 2019. Available at: http://diabetesatlas.org.
Refer to: | Maggie Pfeiffer; monson_maggie@lilly.com; +1 (317) 650-5939 (Lilly Media) |
Kevin Hern; hern_kevin_r@lilly.com; +1 (317) 277-1838 (Lilly Investors) | |
Didier Plaschy; didier.plaschy@ypsomed.com; +41 34 424 41 48 (Ypsomed Media) | |
Thomas Kutt; thomas.kutt@ypsomed.com; +41 34 424 35 55 (Ypsomed Investors) |
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes-301176401.html
SOURCE Eli Lilly and Company
FAQ
What is the agreement between Eli Lilly and Ypsomed about?
When will Lilly commercialize the YpsoPump in the U.S.?
How does the new insulin pump benefit diabetes management?
What are the key features of the YpsoPump?
How many people are affected by diabetes in the U.S.?
